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Abstract
Background: Randomised trials on antibiotic treatment for patients with chronic low back pain and vertebral
endplate changes visible on MRI (Modic changes) have shown mixed results. A possible explanation might be a real
treatment effect in subgroups of the study populations. The purpose of the present study was to explore potential
clinical effect modifiers of 3-months oral amoxicillin treatment in patients with chronic low back pain and type I or
II Modic changes at the level of a previous lumbar disc herniation.
Methods: We performed analyses of effect modifiers on data from AIM, a double-blind parallel-group multicentre
trial. One hundred eighty patients with chronic low back pain, previous disc herniation, Modic change type I (n =
118) or type II (n = 62) were randomised to 3-months oral treatment with 750 mg amoxicillin (n = 89) or placebo
(n = 91) three times daily. The primary outcome was the Roland-Morris Disability Questionnaire (RMDQ) score
(possible values 0–24) at 1-year follow-up in the intention-to-treat population. The predefined minimal clinically
important between-group mean difference was 4 RMDQ points (not reached in the primary analysis of AIM).
Predefined baseline characteristics were analysed as potential effect modifiers, four primary (type I Modic changes,
previous disc surgery, positive pain provocation test, high CRP) and five exploratory (disturbed sleep, constant low
back pain, short duration of low back pain, younger age, and male) using ANCOVA with interaction terms.
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Results: None of the four primary potential effect modifiers had strong evidence of modifying the treatment effect.
In patients younger than 40 years the difference in mean RMDQ score between the treatment groups was − 4.0
(95%CI, − 6.9 to − 1.2), compared to − 0.5 (95%CI, − 2.3 to 1.3) in patients 40 years or older, both in favour of
amoxicillin treatment (exploratory analysis).
Conclusions: We did not find evidence for convincing clinical effect modifiers of antibiotic treatment in patients
with chronic low back pain and Modic changes. Our results for younger age in these explorative analyses should
not affect clinical treatment decisions without confirmation in future studies.
Trial registration: ClinicalTrials.gov NCT02323412, First registered 23 December 2014.
Keywords: Chronic low back pain, Modic changes, Antibiotic, Effect modifier, Subgroup, Randomised, Infection
Background
In most patients with chronic low back pain no specific
or underlying disease can be found. An efficient manage-
ment is often difficult and current treatment options for
low back pain offer at best only small to moderate re-
ductions in pain and disability [1].
Accordingly, there are ongoing attempts to identify
subgroups with specific clinical characteristics that could
lead to effective treatments. A suggested subgroup is pa-
tients with vertebral bone marrow changes extending
from the endplate (Modic changes) visible on magnetic
resonance imaging (MRI), which may be associated with
low back pain [2]. A prominent hypothesis for the eti-
ology of Modic changes is a low-grade bacterial infection
of the adjacent intervertebral disc [3]. A disc herniation
is a suggested precondition for the bacteria to enter into
the disc.
A randomised placebo controlled trial published in 2013
reported that three months of antibiotic treatment offered
substantial improvement of symptoms in patients with
chronic low back pain and type I Modic changes [4]. The
AIM-study (Antibiotics In Modic changes), a reassess-
ment and replication study of the former trial from 2013,
did not find any clinically important difference in outcome
between the treatment groups at three or 12months
follow-up [5]. There was however a small difference be-
tween the groups and an increased variance in outcome
measure in the amoxicillin group compared to the placebo
group, that may suggest a possible treatment effect in sub-
groups [6]. There is also a biological rationale for the het-
erogeneity of treatment effect, as even positive biopsy
studies in patients with Modic changes mostly have a large
proportion of negative samples [7]. There have not been
any reported attempts so far to find effect modifiers of
antibiotic treatment in low back pain based on rando-
mised trials.
The present study was hypothesis-setting [8], meaning
that we attempted to find candidate effect modifiers to
be verified in further hypothesis-testing studies. We
sought subgroups with treatment response, not diagnos-
tic subgroups. The objective of this study was to explore
potential clinical effect modifiers of three months oral
amoxicillin treatment in patients with chronic low back
pain and type I or II Modic changes at the level of a pre-
vious lumbar disc herniation included in the AIM-study.
Methods
Our hypothesis was that one or more of nine predefined
clinical characteristics (described below) modified the ef-
ficacy of three months oral amoxicillin treatment in pa-
tients with chronic low back pain and type I or II Modic
changes at the level of a previous lumbar disc
herniation.
Study design and setting
The present hypothesis-setting analyses were based on
data from the AIM-study, a multicentre, randomised,
double-blind, placebo-controlled, parallel-group trial
with a treatment phase (three months) and a follow-up
phase (nine months). Trial methods have been detailed
previously [9]. The AIM-study was performed in accord-
ance with the Helsinki Declaration. This included being
registered at ClinicalTrials.gov in December 2014 under
the identifier: NCT02323412, approved by the Regional
Committees for Medical Research Ethics - South East
Norway (2014/158/REK sør-øst) before being com-
menced and that all participants gave written informed
consent. This study is reported in accordance with the
CONSORT guidelines [10] and recommendations for re-
search method framework for studies of subgroups in
low back pain [8].
Study population
Patients were recruited from outpatient clinics at six
hospitals in Norway from June 2015 to September 2017.
We included patients with age 18 to 65 years, low back
pain for > 6 months, and low back pain intensity ≥5 on a
0–10 Numerical Rating Scale, a lumbar disc herniation
on MRI in the former two years, and type I and/or type
II Modic changes (with height ≥ 10% of vertebral height
and diameter > 5 mm) at the herniated disc level. Pa-
tients were excluded if they had surgery for disc
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herniation in the last year, or any specific diagnosis that
could explain patient’s low back symptoms (i.e. tumor,
fracture, spondyloarthritis, infection, spinal stenosis) [5].
Randomisation, masking and procedures
Patients were allocated to either three months oral treat-
ment with amoxicillin 750 mg three times daily or pla-
cebo. Allocation was concealed by a computer generated
allocation sequence number and stratified by Modic
change type (I or II) and previous disc herniation sur-
gery (yes or no). All care providers, research staff, statis-
ticians, and patients were blinded to group allocation
during the data collection and analysis. Both treatment
groups received identical capsules, containers, and
labels.
Outcomes and data collection
The score on the Norwegian version of the Roland Mor-
ris Disability Questionnaire (RMDQ) at 1-year follow-up
was used as primary outcome. Secondary outcomes were
Oswestry Disability Index (ODI) 2.0 and low back pain
intensity (0–10 NRS). Serum concentrations of CRP
were measured with the same method for all study cen-
tres (Roche Diagnostics) detecting levels down to 0.6
mg/L. We defined type I Modic changes as primary
(most extensive) or secondary type I Modic changes. Pa-
tients with type II Modic changes, but not type I Modic
changes, were defined as belonging to the type II Modic
change group. Two experienced radiologists independ-
ently evaluated Modic changes and trial eligibility based
on a standardized baseline 1.5 T MRI, and discussed and
solved all disagreements on eligibility. There was no
change in the trial measurements after trial start.
Potential effect modifiers
We preselected, predefined, pre-categorized and ordered
four baseline characteristics as primary potential effect
modifiers and five as explorative potential effect modi-
fiers, based on a biological rationale and previous litera-
ture (Table 1). An additional three variables (NSAIDs
consumption during treatment phase, compliance and
treatment effect at 3 months) described in the Statistical
Analysis Plan were not analysed, as they were measured
after baseline [18].
Statistical analysis
We pre-specified all statistical analyses in a Statistical
Analysis Plan in advance of database locking [19]. We
used the same 50 imputed sets as for the original trial,
where missing RMDQ values (13/180) and missing
values in the secondary outcomes were imputed with a
multiple imputation model using predictive mean
matching as described in the Statistical Analysis Plan for
the main results [20]. Missing values of the potential
effect modifiers were not imputed. All analyses were per-
formed and all figures were made using software pack-
age Stata version 15.
The effect of each of the nine potential effect modifiers
was analysed with an ANCOVA model on the intention-
to-treat population using RMDQ scores at 1-year follow
up as the dependent variable. Independent variables in-
cluded the baseline RMDQ score, treatment group, the
effect modifier, treatment group multiplied with the ef-
fect modifier (interaction term), and the stratification
variables embedded in the randomisation (Modic change
type and previous disc surgery). The hypothesis of
whether there is a difference in the treatment effect
across levels of the potential effect modifier was assessed
by the interaction term [18, 21]. We also report mean
differences between the antibiotic and the placebo group
for patients in each category of the subgroup by pairwise
comparison of margins in the model with the interaction
term (stratified analysis). Using the analysis of Modic
change type as an example, the stratified analysis com-
pared the predicted mean in the amoxicillin group with
the predicted mean in the placebo group for only those
patients who had type I Modic changes (and then separ-
ately for those who had type II Modic changes). The
stratified analyses intend to answer “what is the effect of
the treatment in each category of the subgroup?” The
significance test of the interaction term intends to an-
swer “was the observed difference in the treatment effect
between the two categories of the subgroup due to a
statistical significant effect modification?” Our analyses
should not be confused with analyses of prognostic fac-
tors, which is another type of subgroup analyses in
which it is not possible to elucidate if the observed sub-
groups are due to the treatment or not [8].
To explore whether any effect modifier was consistent
across related outcomes we repeated the analyses using
ODI and low back pain intensity as dependent variables
[18]. In addition, to assess if any effect modification
remained when adjusted for the other potential effect
modifiers (independency of effect) [18], we performed
ANCOVA with baseline RMDQ score, treatment groups,
all nine effect modifiers, all nine potential effect
modifier-treatment group interactions terms, and the
stratification variables as independent variables. We ig-
nored any findings in effect modifiers that did not have
a clinically relevant result in the main analysis, as we
intended to just evaluate consistency and independency
of the results (of individual effect modifiers for RMDQ)
and wanted to reduce the problem with multiple testing.
We regarded a real effect of antibiotics more likely if
present across many outcome measures.
As in the original trial, we predefined the minimal
clinically important between-group difference in mean
RMDQ score as 4. The AIM-study was powered for
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secondary analyses separately for type I and type II
Modic changes, in which 66 patients were needed to de-
tect (β = 0.1, α = 0.05) a difference of 4 (standard devi-
ation 5) in mean RMDQ score between the two
treatment groups. To equally power effect modifier ana-
lyses with interaction terms at the identical effect of the
modifier as for the between-group difference, a roughly
four times larger sample (66 × 4 = 264 patients) would be
needed [22]. However, since the present sample (n =
180) give a somewhat lower power of about 75% to as-
sess effect modifier analyses (assuming evenly sized
groups and an identical effect size of the modifier as
for the between-group difference), we focused on the
size and direction of the effects, rather than relying
only on the statistical significance of the interaction
term. The statistical power was likely somewhat en-
hanced as we included baseline values of the out-
come, and the stratification variables, as covariates.
We also analysed the potential effect modifiers in a
prioritized order. As the analyses were hypothesis-
setting only, we did not adjust the significance level
due to multiple testing [8].
Table 1 Predefined potential effect modifiers of interest
Potential effect modifier Biological rationale
Primary analyses
1. Modic changes type I
We expected a larger treatment effect in type I compared to
type II.
Type I Modic changes are more strongly associated with low back
pain [11]. In animal models, injecting C.acne into intervertebral
discs induced type I Modic changes [12, 13].
2. Previous disc surgery at level with Modic changes
We expected a larger treatment effect in patients with previous
disc surgery compared to those without.
Low-grade discitis might be a complication of disc surgery due to
introduction of bacteria into the disc during the surgical procedure.
The randomised trial from 2013 with a high number of patients with
previous surgery found effect of antibiotic treatment [4], while a case
series with few patients with previous surgery was negative [14].
3. Positive pain provocation test
We expected a larger treatment effect in patients with a positive
Springing test (patient reported pain with pressure applied to
lumbar transverse processes) compared to those with a negative
Springing test.
Spinal tenderness may indicate regular spondylodiscitis [15]. Springing
test is found to be borderline significant discriminator between patients
with and without Modic changes [16].
4. Elevated CRP (C-reactive protein)
We expected a larger treatment effect in those with higher CRP. The
predefined cut-off values for CRP were changed from 3mg/L and
10 mg/L to 5 mg/L due to too few patients in the predefined
categories.
CRP in serum is associated with bacterial infection and inflammation.
Exploratory analyses
1. Disturbed sleep
We expected a larger treatment effect in those with disturbed sleep
than in those without. Disturbed sleep was defined as a ≥ 2 score on
the Oswestry Disability Index item 7 (sleep scale), i.e. less than 6 h
sleep to no sleep because of pain.
Night-time pain may indicate infectious spondylodiscitis [15].
2. Constant low back pain
We expected a larger treatment effect in those patients with
constant low back pain compared to those with fluctuating low
back pain.
Constant pain may indicate regular spondylodiscitis [15].
3. Short duration of low back pain
We expected a larger treatment effect in those with short duration
of symptoms compared to those with longer duration of symptoms.
The predefined categorization (< 1 year, 1–2 years and≥ 2 years) was
dichotomized into < 2 years and≥ 2 years due to too few patients
with symptoms < 1 year.
Recent disc herniation could have increased perfusion in the disc as
part of disc repair, thereby increasing absorption of amoxicillin.
4. Younger age
We expected a larger treatment effect in patients < 40 years of age
compared to those ≥40 years of age.
C.acne could be more prevalent in discs of young patients [17].
5. Male gender
We expected a larger treatment effect in men compared to women. C.acne could be more prevalent in discs in men than in women [17].
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Results
Of 180 included patients, 89 were randomised to amoxi-
cillin and 91 to placebo. One patient in the amoxicillin
group and one patient in the placebo group did not re-
port the baseline RMDQ. Four patients in the amoxicil-
lin group and seven patients in the placebo group did
not report RMDQ at 1-year follow up. All randomised
patients were included in the intention-to-treat analyses
(multiple imputations were used to account for missing
values in the primary and secondary outcomes).
The distribution of the potential effect modifiers at
baseline is presented in Table 2. Elevated CRP was
present in 14/89 (17%) in the amoxicillin group and in
7/91 (8%) in the placebo group. The distribution of base-
line characteristics within each potential effect modifier
is presented in Table S1 in the Supplementary
Appendix.
Primary analysis
The treatment effect (the adjusted mean difference in
RMDQ score between the amoxicillin group and the pla-
cebo group at 1 year) for patients with type 1 Modic
changes was − 2.3 (95% CI, − 4.2 to − 0.4), with type 2
Modic changes − 0.1 (95% CI, − 2.7 to 2.5), and with a
difference between the two of 2.2 (95% CI, − 1.0 to 5.4)
(estimates from the interaction term) (Fig. 1). The simi-
lar treatment effect for patients with previous disc sur-
gery was − 3.2 (95% CI, − 6.6 to 0.1), and for patients
without previous disc surgery − 1.1 (95% CI, − 2.8 to 0.6;
interaction term, − 2.1; 95% CI, − 5.8 to 1.6), for patients
with negative pain provocation test − 4.3 (95% CI, − 8.5
to − 0.1), for patients with positive pain provocation test
− 1.2 (95% CI, − 2.8 to 0.5; interaction term, 3.1; 95% CI,
− 1.4 to 7.6), for patients with low CRP − 2.0 (95% CI, −
3.7 to − 0.4), and for patients with elevated CRP 2.9
(95% CI, − 1.7 to 7.6; interaction term, 4.9; 95% CI, 0.0
to 9.9). The direction of effect for pain provocation test
and CRP was opposite of the predefined hypothesis.
Exploratory analysis
The adjusted mean difference in RMDQ score between
the treatment groups for those with disturbed sleep was
0.2 (95% CI, − 2.0 to 2.3), and for those with undisturbed
sleep − 3.3 (95% CI, − 5.5 to − 1.1; interaction term, 3.5;
95% CI, 0.4 to 6.6) (opposite direction of the predefined
hypothesis) (Fig. 1). In younger patients, i.e. < 40 years,
the adjusted mean difference was − 4.0 (95% CI, − 6.9 to
− 1.2), and in those ≥40 years old − 0.5 (95% CI, − 2.3 to
1.3; interaction term, 3.6; 95% CI, 0.2 to 6.9), in favour
of amoxicillin (same direction of effect as hypothesised).
In the multivariate analysis including all effect modi-
fiers and their interaction terms the adjusted mean dif-
ference in RMDQ score between the treatment groups
was 3.5 (95% CI, − 0.1 to 7.0) points larger for those
Table 2 Distribution of the potential effect modifiers according
to treatment groups
Amoxicillin (n = 89)
Number of patients
Placebo (n = 91)
Number of patients
Primary effect modifiers













< 5mg/L 70 82











Duration of low back pain
< 2 years 31 25
≥ 2 years 58 65
Missing 0 1
Age
< 40 years 28 27







ODI Oswestry Disability Index. Score from 0 to 100. Higher scores indicate
more severe pain and disability
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Fig. 1 Forest plot with results for RMDQ (primary outcome). The difference in mean RMDQ score between the treatment groups (size of
treatment effect) with 95% confidence interval is shown in black on the right for each of the two categories of each potential effect modifier. The
difference in size of treatment effect between the two categories (estimated by the interaction term), with 95% confidence interval and p-values
is shown in red. RMDQ Roland-Morris Disability Questionnaire. Score from 0 to 24. Higher scores indicate more severe pain and disability. CRP C-
reactive protein. ODI Oswestry Disability Index. Score from 0 to 100. Higher scores indicate more severe pain and disability. LBP Low back pain
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Fig. 2 Forest plot with results for ODI (secondary outcomes). The difference in mean ODI score between the treatment groups (size of treatment
effect) with 95% confidence interval is shown in black on the right for each of the two categories of each potential effect modifier. The difference
in size of treatment effect between the two categories (estimated by the interaction term), with 95% confidence interval and p-values is shown in
red. CRP C-reactive protein. ODI Oswestry Disability Index. Score from 0 to 100. Higher scores indicate more severe pain and disability. LBP Low
back pain
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Fig. 3 Forest plot with results for low back pain intensity (secondary outcome). The difference in mean low back pain intensity score between
the treatment groups (size of treatment effect) with 95% confidence interval is shown in black on the right for each of the two categories of
each potential effect modifier. The difference in size of treatment effect between the two categories (estimated by the interaction term), with
95% confidence interval and p-values is shown in red. CRP C-reactive protein. ODI Oswestry Disability Index. Score from 0 to 100. Higher scores
indicate more severe pain and disability. LBP Low back pain
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younger than 40 years compared with those aged 40
years and older (Table S2). The relationship between age
and change in RMDQ from baseline to one year is
shown in Fig. S1 in the Supplementary Appendix.
The primary potential effect modifiers had no or only
a small effect on ODI or low back pain intensity in the
hypothesized direction. The treatment effect did not
change a great deal across age categories (9.2; 95%CI 1.6
to 16.8) with a moderate treatment effect in younger pa-
tients (− 11.2; 95%CI − 17.6 to 4.8) on ODI (Fig. 2), but
not on low back pain intensity (Fig. 3).
Discussion
In this study, none of the four primary potential ef-
fect modifiers (type I Modic changes, previous disc
surgery, positive pain provocation test, high CRP) had
a clinically relevant or statistically significant impact
on the effect of antibiotic treatment in patients with
chronic low back pain and type I or II Modic changes
at the level of a previous lumbar disc herniation. Pa-
tients with low CRP had better treatment effect than
those with high CRP, opposite of our prespecified dir-
ection, and mainly driven by better RMDQ scores in
the placebo compared to the amoxicillin group for
those with high CRP, which we find biologically im-
plausible. In the exploratory analyses we observed a
small effect modification of disturbed sleep in the op-
posite of the prespecified direction. We observed a
modifying effect of age; patients younger than 40 years
had a clinically relevant and statistically significant ef-
fect of antibiotic treatment on the RMDQ and ODI,
but not on low back pain intensity, and the effect on
RMDQ diminished when all effect modifiers were
analysed simultaneously. A treatment effect in youn-
ger patients might seem biologically plausible, since
they might be more likely to have C.acnes in their
discs (Table 1) and relatively less likely to have Modic
changes as part of age related degeneration compared
to older patients [17, 23]. However, these explorative
results should be interpreted with great caution, and
require confirmation in future studies. Further, our
predefined subgroups should be interpreted as surro-
gate subgroups, meaning that there is no claim of a
causal mechanism involved [24]. E.g there is no claim
that age in itself cause effect modification, but rather
that age may be associated with an unknown factor
that could cause effect modification.
The most important limitation of this study is the lack
of a confirmed bacterial infection in the disc prior to
antibiotic treatment. Second, there is a further limitation
due to possibly insufficient statistical power, leading to
increased risks of type I and II errors [25]. Our results
indicating age as an effect modifier may represent a type
I error due to multiple testing. The present findings
should therefore not influence clinical practice. They
could still be important in the design and interpret-
ation of future trials on antibiotic treatment for pa-
tients with low back pain and Modic changes, and of
studies on the etiology of Modic changes. Third, we
cannot exclude a possible treatment effect in sub-
groups were the lower end of the confidence interval
crosses the predefined limit for clinically important
difference (e.g. type 1 Modic changes, previous disc
surgery and constant pain). However, the most likely
treatment effects in these subgroups are still below
clinical importance.
Some of the inclusion- and exclusion criteria used in
the AIM study limit the generalizability of the results of
the present study. AIM only included patients with a
previous disc herniation within the last two years. This
could theoretically make the trial more likely to detect a
treatment effect of antibiotics, since the infection theory
of Modic changes suggests that a disc herniation is
needed for bacteria to enter into the disc [3, 26]. How-
ever, this theory has not been confirmed and it is uncer-
tain how our results for treatment modifiers would have
been in patients without a previous disc herniation. Fur-
ther, our results are not generalizable for patients not
fulfilling the inclusion criteria, ie lower baseline low back
pain intensity, outside our age limits, and with other
comorbidities.
Microbiological studies on disc biopsies show mixed
results, and it is still uncertain whether the observed
C.acnes in such studies are partly or completely ex-
plained by contamination. However, proteomic analyses
of degenerated discs did find evidence of response to
gram positive bacterial infection that is difficult to ex-
plain by contamination [27]. Further trials with anti-
biotic treatment in back pain should preferably be
performed on patients with confirmed infection, either
microbiologically or other methods.
Conclusions
We did not find evidence for convincing clinical effect
modifiers of antibiotic treatment in this secondary ana-
lysis of the AIM study. Age may possibly act as an effect
modifier, requiring attention in further studies, but the
present results should not affect clinical practice without
further confirmation.
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